CommercialCoverageMedium impact
08.01.69e, Atezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza TM)
Independence Blue Cross·Oncology·Pharmacy
Effective date
Apr 1, 2025
We identified it
Jun 19, 2026
Summary
This is a commercial insurance policy update for Atezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza™), effective April 1, 2025. The specific changes are not detailed in the summary provided, but this appears to be a pharmacy policy update that may affect coverage, prior authorization, or billing requirements for these cancer immunotherapy medications.
Action Required
By April 1, 2025: Billing team should review the full policy details at the provided URL to understand specific changes to Atezolizumab coverage and billing requirements. Update any prior authorization workflows and verify current billing practices align with the new policy requirements for both Tecentriq and Tecentriq Hybreza formulations.